Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C |
Hwang, Yong
(Department of Medicine, Konkuk University School of Medicine)
Kim, Won (Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) Kwon, So Young (Department of Medicine, Konkuk University School of Medicine) Yu, Hyung Min (Department of Medicine, Konkuk University School of Medicine) Kim, Jeong Han (Department of Medicine, Konkuk University School of Medicine) Choe, Won Hyeok (Department of Medicine, Konkuk University School of Medicine) |
1 | Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004;117:10-13. DOI |
2 | Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf ) 1999;50:503-509. DOI |
3 | Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2005;165:2206-2212. DOI |
4 | Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003;13:547-551. DOI |
5 | Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004;89:3656-3661. DOI |
6 | Costelloe SJ, Wassef N, Schulz J, et al. Thyroid dysfunction in a UK hepatitis C population treated with interferonalpha and ribavirin combination therapy. Clin Endocrinol (Oxf ) 2010;73:249-256. |
7 | Morisco F, Mazziotti G, Rotondi M, et al. Interferonrelated thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis 2001;33:247-253. DOI |
8 | Jamil KM, Leedman PJ, Kontorinis N, et al. Interferoninduced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol 2009;24:1017-1023. DOI |
9 | Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002;251:400-406. DOI |
10 | Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of highdose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-291. DOI |
11 | Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferon- alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: metaanalysis. J Gastroenterol Hepatol 2007;22:472-476. DOI |
12 | Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006;21(1 Pt 2):319-326. DOI |
13 |
Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. Thyroid disease in chronic hepatitis C infection treated with combination interferon- |
14 | Huang JF, Chuang WL, Dai CY, et al. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon- alpha and ribavirin combination therapy. J Viral Hepat 2006;13:396-401. DOI |
15 | Vasiliadis T, Anagnostis P, Nalmpantidis G, et al. Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore 2011;40:394-400. |
16 | Geul KW, van Sluisveld IL, Grobbee DE, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: associations with serum lipids. Clin Endocrinol (Oxf) 1993;39:275-280. DOI |
17 | Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J Gastroenterol Hepatol 2009;24:1024-1029. DOI |
18 | Antonelli A, Ferri C, Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 2009;6:633-635. DOI |
19 | Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf ) 1995;43:55-68. DOI |
20 | Tran HA, Malcolm Reeves GE, Gibson R, Attia JR. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol 2009;24:1163-1168. DOI |
21 | Rotondi M, Minelli R, Magri F, et al. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. Eur J Endocrinol 2007;156:409-414. DOI |
22 | Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008;12:611-613. DOI |
23 | Antonelli A, Ferri C, Fallahi P, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006;16:563-572. DOI |
24 | Kim do Y, Kim IH, Jeong SH, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586-594. DOI |
25 | Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. DOI |
![]() |